southtownstar
ADMIRABLE 
Weather Updates

Roche to buy US biotech firm InterMune for $8.3B

BERLIN — Swiss pharmaceutical company Roche says it will buy a California-based developer of treatments for lung diseases, InterMune Inc., in a deal worth $8.3 billion.

Roche said Sunday the companies have reached an agreement under which Roche will acquire InterMune in an all-cash transaction, paying $74.00 per InterMune share. That’s a premium of 38 percent over InterMune’s closing price on Friday.

The Swiss firm says the acquisition the biotechnology company, based in Brisbane, California, “will allow Roche to broaden and strengthen its respiratory portfolio globally.”



© 2014 Sun-Times Media, LLC. All rights reserved. This material may not be copied or distributed without permission. For more information about reprints and permissions, visit www.suntimesreprints.com. To order a reprint of this article, click here.